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A B S T R A C T
Chlorpromazine (CPZ) is a neuroleptic drug and prototype compound used to study intrahepatic cholestasis. The
exact mechanisms of CPZ induced cholestasis remain unclear. Rat hepatocytes, or a sandwich culture of rat and
human hepatocytes, have been the most commonly used models for studying CPZ toxicity in vitro. However, to
better predict outcomes in pre-clinical trials where cholestasis may be an unwanted consequence, a human in
vitro model, based on human HepaRG cells, capable of real-time, non-invasive and label free monitoring,
alongside molecular investigations would be beneﬁcial. To address this we used the human hepatic HepaRG cell
line, and established concentrations of CPZ ranging from sub-toxic, 25 μM and 50 μM, to toxic 100 μM and
compared them with untreated control. To assess the eﬀect of this range of CPZ concentrations we employed
electrical cell-substrate impedance sensing (ECIS) to measure viability and cell membrane interactions alongside
traditional viability assays, immunocytostaining and qRT-PCR to assess genes of interest within adaptive and
inﬂammatory pathways. Using these methods, we show a concentration dependant response to CPZ involving
pro-inﬂammatory pathway, loss of tight junctions and membrane integrity, and an adaptive response mediated
by Cytochrome P450 (CYP) enzyme activation and up-regulation of membrane phospholipid and xenobiotic
transporters. In conclusion, structural changes within the membrane caused by sub-toxic and toxic concentra-
tions of CPZ negatively impact the function of the cellular membrane. Damage to eﬄux transport proteins caused
by CPZ induce cholestasis alongside downstream inﬂammation, which activates compensatory responses for cell
survival.
Lay summary: Chlorpromazine is a drug used to treat patients with schizophrenia, which has a known asso-
ciation with liver damage. Here we show that it causes inﬂammation and alters the cell membranes in liver and
bile duct cells similar to what is seen within a human population. The initiation of the inﬂammatory response
and changes to cellular structure may provide insight into the damage and disease process and inform medical
treatment.
1. Introduction
Chlorpromazine (CPZ) has long been used as an in vitro model of
intrahepatic cholestasis (IHC), as there is evidence that it causes
impaired biliary function, though the mechanisms behind this are not
fully understood and side eﬀects are usually idiosyncratic [1–5]. Cho-
lestasis is a condition characterized by impaired ability of the bile ducts
to secrete bile acids, bilirubin and cholesterol [6]. There is currently a
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need within the pharmaceutical industry to predict cholestasis in vitro
before drugs are submitted for pre-clinical trials. Investigating the
mechanisms behind CPZ toxicity may be informative for studies of
other xenobiotics known to target the biliary system/cholangiocytes
and aid in pre-clinical toxicity studies.
HepaRG cells are an intrinsic co-culture of hepatocyte and cho-
langiocyte-like cells. In comparison to other human hepatic cell lines,
such as C3A and HepG2, the HepaRG cell line has been found to be
more metabolically active, has an improved culture longevity and sta-
bility of 4–6 weeks in culture [7]. The major advantages of utilising this
cell line is the ability to study, in one culture, the interaction of hepa-
tocyte and cholangiocyte-like cells. This results in a culture of polar
hepatocyte cords alongside cholangiocytes, and the formation of tight
junctions between the cells within 8 days [8]. Tight junctions consist of
a network of proteins that act as a barrier, maintaining cell membrane
integrity and controlling exchange of molecules and ions across the
membrane. Within hepatocytes, tight junctions are critical in main-
taining cellular integrity, preserving polarity, and formation of bile
canaliculi [8]
Cell based impedance assays are an emerging technology due to
their high sensitivity and quantitative nature. Cells behave as insulating
particles that alter impedance measurements when cultured on top of
micro-electrodes. Therefore, an increase in impedance is a reﬂection of
cellular growth kinetics. Electrical cell-substrate impedance sensing
(ECIS) is a label-free, real-time monitoring technology where changes
associated with cellular events are reﬂected in the measured im-
pedance, which encompasses resistive and capacitive components. A
major advantage of ECIS is its ability to decouple parameters of cell
growth and cell-cell interaction, through mathematical modelling, into
changes in membrane integrity, quality of basolateral adhesion and
cell-cell tight junctions, all contributing to changes in impedance over
time [9,10].
This quantiﬁcation is possible due to the multi-frequency biosensor
within the ECIS Zθ instrument developed by Applied Biophysics. At low
frequencies (102–10 4Hz), the current is unable to pass through the cell
membrane so the behaviour of the current is dependent on its ability to
move through intercellular junctions. At this frequency, the measured
resistance correlates biologically to the integrity of tight junctions and
basolateral adhesion. Changes in these parameters can be directly
correlated to changes in expression of zonular occludins 1 (ZO1). At
higher frequencies (> 10,000 Hz), the current is able to pass through
the cells. Capacitive measurements are preferred at these frequency
ranges as they reﬂect the electrode cell coverage and reveal data on the
integrity of the cell plasma membrane.
Previously, we have used ECIS technology to demonstrate disrup-
tion of HepaRG cell tight junctions with a model hepatotoxin acet-
aminophen (APAP) [8]. Here we applied this technique to a cholestatic
compound CPZ, alongside traditional viability assays (PrestoBlue and
Total ATP), immunocytostaining of cytoskeletal component F-actin and
tight junction protein ZO1. Molecular investigations into apoptotic,
oxidative stress and inﬂammatory pathways aid our understanding of
the mechanism of toxicity and development of IHC.
2. Materials and methods
Several studies on the plasma concentrations of CPZ in humans were
undertaken in the 1970s when the drug was still readily prescribed.
Two groups, Curry et al., and Wiles et al., both describe variations in
plasma levels between patients receiving the same dose of CPZ and cite
these variations to diﬀerences in absorption and metabolism of the drug
[11,12]. This seems in line with the idiosyncratic nature of this drug
where patients can have the same plasma level of CPZ but one receives
therapeutic results while the other does not. This can also be compared
to toxicity where plasma levels between patients are consistent, but one
patient may experience toxicity at therapeutic plasma levels and an-
other may not. Acutetox: ‘an in-vitro test strategy for predicting human
acute toxicity’ describe a series of 8 fatal cases where blood plasma
concentration was between 3 and 35mg/l [13]. This variance is again
explained by diﬀerence in intestinal metabolism [14]
As such we use Antherieu’s concentrations based on in vitro toxicity
with an IC50 of 80 μM (50% of cells are viable) where 25 μM remains
non-toxic, 50 μM is sub-toxic and 100 μM results in a toxic concentra-
tion. This in vitro range encompasses the variation of non-toxic – toxic
concentrations described by Acutetox [13].
On day 8 of culture human HepaRG cells were treated with these
concentrations of CPZ and analysis was undertaken using ECIS, viability
assays, immunostaining and qRT-PCR.
2.1. Drug
CPZ was obtained from Sigma-Aldrich (Product no: C8138) and
stored at room temperature. A stock of 100mM in PBS buﬀer was ali-
quoted and stored at -20C. CPZ dilutions were made in HepaRG™
Maintenance and Metabolism Medium (ADD620).
2.2. Cell culture
HepaRG cells (HPR116 – cryopreserved HepaRG™ cells; Biopredic
Int’l, Rennes, France) were cultured using suppliers’ protocols. Williams
E Medium with GlutaMAX™ was used as the basal medium with sup-
plements purchased from Biopredic Int’l. Cells were seeded in General
Purpose HepaRG® medium (ADD670) on day 0 at 2.4× 105/cm2into 8
well Ibidi arrays with 10+ electrodes per well for ECIS impedance
measurements and on Corning 96 well and 24 well tissue culture plates
for assays and immunocytochemistry respectively. On day 3 media was
changed to HepaRG™ Maintenance and Metabolism Medium (ADD620)
and renewed every other day. Cultures were monitored for 8 days be-
fore exposure to CPZ.
2.3. Immunocytostaining
The morphology of HepaRG cells cultured on 24 well plates was
regularly assessed by microscopy before addition of 0, 25, 50 or 100μM
CPZ on day 8 for 24 h. For immunocytostaining cells were ﬁxed in 4%
buﬀered formaldehyde solution (Pierce, 28908, Thermo Scientiﬁc) for
1 h, permeabilised with 0.1% Triton-X 100 (X100; Sigma-Aldrich) in
Tris-buﬀered Saline (TBS; T6664; Sigma-Aldrich) for 30min, and
blocked with 5% goat serum (G6767; Sigma-Aldrich) in TBS for one
hour. Tight junctions were stained using primary antibody to ZO1 (SC
10,804 Santa Cruz 1:50 dilution) incubation overnight and washed
before addition of secondary antibody goat-anti-rabbit Alexa Fluor 488
(11,034; Life Technologies; 1:1000 dilution). Hoechst 33,342 (HS1492;
Life Technologies; 10 μg/ml) and Phalloidin-TRITC (R415; Life
Technologies; 3 U/mL 1:200 dilution) were used to stain nuclei and F-
actin cytoskeleton respectively. Manufacturer’s guidelines for Hoechst
incubation suggest 5–30minutes at room temperature as staining in-
tensity may increase with time. Manufacturer’s guidelines for
Phalloidin suggest incubation from 30 to 60minutes at room tem-
perature. For ease of experimental design, Hoechst, Phalloidin and
secondary antibody were added at the same time and were incubated
for 2 h. While it is not necessary to incubate ﬁxed cells with Hoechst or
Phalloidin for this length of time, the nature of the chemical staining is
such that no detrimental eﬀect has been seen when incubating 2 h
alongside secondary antibody. Fluorescent imaging was taken with an
EVOS Auto FL imaging platform (Thermo Scientiﬁc) for cytoskeleton
labelling. All images x20 magniﬁcation. Morphology of cultured cells
was monitored throughout culture.
2.4. Viability assays
Cells were seeded on a 96 well standard tissue culture plate and
cultured for 8 days. After 24-hour treatment with CPZ, supernatant was
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removed and PrestoBlue® (A-13262; Life Technologies Paisley, UK) was
added to each well and incubated for 30min at room temperature.
Fluorescence was measured using a GloMax+Microplate Multimode
Reader (Promega, Southampton, UK) at 520 nm per vendor’s instruc-
tions. After treatment with PrestoBlue assay wells were washed and
cells lysed using Promega CellTiter-Glo®Luminescent Cell Viability
Assay (G7570; Promega) luciferase based assay. After 30min incuba-
tion at room temperature, detection agent was added and biolumines-
cent signals measured with the GloMax plate reader.
2.5. Molecular analysis
2.5.1. RNA isolation and reverse transcription-quantitative polymerase
chain reaction (qRT-PCR)
RNA was extracted from untreated control and CPZ treated (25μM
and 50μM) HepaRG cells. Total RNA was isolated using TRIzol™
(Thermo Fisher Scientiﬁc, Inc.), following the manufacturer's instruc-
tions. RNA was quantiﬁed using a Nanodrop instrument (ND 1000
Spectrophotometer). Quality and purity of RNA was examined using
260/280 and 260/230 absorbance ratios. All samples had 260/280
ratios above 1.8. The nanoScript to RT kit (PrimerDesign, UK) was used
to convert 1 μg of RNA to cDNA following the manufacturer's instruc-
tions.
The quantitative validation of the expression of selected genes was
assessed by RT-qPCR, as previously described [15] using custom Pri-
merDesign primers and applying the PrecisionPLUS qPCR Master Mix
(PrimerDesign, UK), following the manufacturer's protocol. Primers are
listed in Table 1. Ampliﬁcation was performed for each cDNA (25 ng)
sample in triplicate. Reactions were run in triplicate on a LightCycler
Instrument (Roche LightCycler® 96 System). Running conditions were
95 °C 2min, followed by 40 cycles of 95 °C 15 s and 60 °C 60 s. Data
from qRT-PCR were normalized to multiple internal control genes
(GAPDH, UBC, TOP1) with the geNorm algorithm as described by
Vandesompele et al., 2002 [16,17].Results are presented as fold-
changes in gene expression relative to untreated control calculated with
the ΔΔCq method.
2.5.2. Identiﬁcation of suitable reference genes
As previously described, the geNorm Housekeeping Gene Selection
Kit (PrimerDesign) was used to evaluate expression of 12 commonly
used housekeeping genes in untreated control and CPZ treated cells.
Selected reference genes were: 18S (18S ribosomal RNA subunit), β-
Actin(beta-actin), ATP5b (ATP synthase subunit 5b), B2M (beta-2mi-
croglobulin), TOP1 (topoisomerase 1), CYC1 (cyclin D1), EIF4a2 (eu-
karyotic initiation factor 4a2), GAPDH (glyceralde-hyde-3-phosphate
dehydrogenase), RPL13a (ribosomal protein L13a), SDHA (succinate
dehydrogenase complex, subunit A), UBC (ubiquitin C), and YHWAZ
(phospholipaseA2). The geNorm output ranked the candidate reference
gene according to their expression stability (M). The top three reference
genes (GAPDH, UBC, TOP1) were used in subsequent analyses.
2.6. Electric cell-substrate impedance sensing (ECIS) – impedance assay
The ECIS Zθ system (Applied Biophysics) was used to measure, in
real time, total impedance using a multiple frequency model. Using the
ECIS-Zθ software’s built-in mathematical model we were able to ana-
lyse the electrical current pathways which allows the data to be de-
convolved into cell-cell tight junctions (Rb), cell-electrode basolateral
adhesion (α) and cell membrane capacitance (Cm). HepaRG cells were
seeded in 8 well 10+ electrode (8w10E+) cultureware (Ibidi).
Diﬀerentiation of HepaRG cells into a stable and conﬂuent co-culture of
cholangiocyte-like cells and hepatocytes was monitored using phase
microscopy alongside the ECIS–Zθmode over 8 days (n=3). A baseline
for conﬂuency before addition of compound, had already been estab-
lished in our lab [8]. ECIS measurements were taken at 180 s intervals
over a 500 Hz to 64 kHz frequency range. At day 8 HepaRG cells were
challenged with a serial dilution of CPZ. Impedance measurements
were normalized to the values at 0 h and modelled to a no cell control.
2.7. Statistical analyses
Data analysis and graphical illustration were performed with
GraphPad Prism 5.0 and 7.0 (GraphPad Software, Inc., San Diego, CA,
USA). Experiments were performed in triplicate, unless stated other-
wise, and results are presented as mean ± SD. Diﬀerences between the
diﬀerent culture conditions (with or without CPZ) were detected ap-
plying a one way Anova with post hoc Tukey test. Results were con-
sidered signiﬁcant at p < 0.05. Impedance data analysed using Matlab.
3. Results
3.1. Immunocytostaining
Cytoskeletal changes were assessed by staining with phalloidin at
24 h post CPZ treatment. Little diﬀerence was seen between control and
25μM CPZ treated cells. Using 50μM concentration, some degradation
of F-actin cytoskeleton was evident. At 100μM, while there were still
some nuclei present as evidenced by Hoechst nuclei staining (blue),
there were few intact cells present and loss of phalloidin staining was
evident.
The network of ZO1 staining pattern was not signiﬁcantly diﬀerent
between control and 25 μm CPZ. Though it did appear that there was
more intense staining, possibly compensatory at 25 μm. At 50μM ZO1
staining there was lack of organisation of hepatocyte chords as well as
disruption to network of tight junction protein. At 100μM little to no
cell/cell contact could be demonstrated by ZO1 staining (Fig. 1).
3.2. Total ATP and PrestoBlue assays
There was no statistical diﬀerence in cellular viability between
control and CPZ treated samples at any concentration as evidenced by
total ATP and PrestoBlue assays (n= 3) (Fig. 2).
Table 1
List of primers for genes of interest used within this study.
Gene Forward Primer Reverse Primer Accession #
ABCB1 AACACCACTGGAGCATTGAC TACAGCAAGCCTGGAACCTA NM_000927
ABCB4 GAAGCAAAGAAACTCAATGTCCAG TAGGCAATATTCTCGGCAATGC NM_000443.3
ABCB11 CACAGACCAGGATGTTGACAGG GTCTCAAGTGCTTCAATGAACCG NM_003742.2
IL6 GCAGAAAACAACCTGAACCTT ACCTCAAACTCCAAAAGACCA NM_000600
BAX ATGGAGCTGCAGAGGATGAT CAGTTGAAGTTGCCGTCAGA NM_138761
BCL2 GAGGTCACGGGGGCTAATT GAGGCTGGGCACATTTACTG NM_000633
TNF AGGTTCTCTTCCTCTCACATAC ATCATGCTTTCAGTGCTCATG NM_000594
HNF GACCTCTACTGCCTTGGACAA GATGAAGTCGGGGGTTGGA NM_000457
NRF2 CCCAGCACATCCAGTCAGA CAGTCATCAAAGTACAAAGCATCT NM_006164
CYP3 A4 ACCGTAAGTGGAGCCTGAAT AAGTAATTTGAGGTCTCTGGTGTT NM_017460
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Viability assays were not in agreement with immunocytostaining at
100 μm. This indicated good viability of un-adhered cells within cul-
ture. This discrepancy can be explained by possible disruption of
adhesion through wash steps, ﬁxation and permeabilisation of the im-
munocytostaining that did not aﬀect viability within the experiment
period.
Fig. 1. Immunocytostaining of HepaRG cells after 24 h ex-
posure to increasing concentrations of CPZ: (A HepaRG cells
double stained on day 8 with Hoechst (blue nuclei stain) and
Phalloidin (red F-actin cytoskeletal stain) reveals distinct
pericanalicular-cytoskeletal/ TJ-associated F-actin bands in
control cells with decreased staining at low-dose (25 μM) CPZ
and progressively less intense staining at higher CPZ doses.
(B) Double staining of HepaRG cells on day 8 with Hoechst
(blue nuclei stain) and ZO1 (green staining indicating tight
junction protein) demonstrated reduced intensity of the he-
patic tight junction-associated structural protein ZO1. ZO1,
progressively decreases, as the hepatic cord phenotype is
compromised at 50 and 100 μM concentrations. (C) Untreated
control and 25 μM CPZ shown with magniﬁed ﬁeld showing
membrane bound ZO1 (For interpretation of the references to
colour in this ﬁgure legend, the reader is referred to the web
version of this article).
Scale bars represent 160 nm, all pictures taken on EVOS ﬂ-
auto at x20 magniﬁcation. Figures representative of 3 in-
dependent experiments with 3 technical replicates per ex-
periment.
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3.3. Eﬀects of CPZ on tight junctions and basolateral adhesion
Total impedance (Z) is a composite value of resistive and capacitive
parts, which can be further deconvolved into parameters that can
measure biological behaviour.
Multiple frequency measurements using ECIS Zθ allowed modelling
of the following parameters corresponding to biologically signiﬁcant
cell behaviour; Tight junctions (Rb), cell-electrode basolateral ad-
herence (α), and cell membrane integrity (Cm).
The resistance showed a highly-sensitive concentration-response to
CPZ with a decrease of impedance at all frequencies (Fig. 3A). The
lowest concentration, 25μM, had least eﬀect across all parameters.At
50μM both Rb and Cm decreased, however, after 5 h some recovery was
seen (Fig. 3 B&D). 100μM CPZ showed the greatest loss of Cm with a
decrease of approximately 50% within the ﬁrst 2 h of administration,
but also showed recovery 6 h post administration which continued
throughout the duration of the experiment (Fig. 3D). Basolateral ad-
hesion was the least eﬀected parameter though some dose dependant
response was seen (Fig. 3C).
Taken together deconvolved and resistance measurements were
informative as to the mechanistic eﬀect of CPZ revealing that tight
junctions had been disrupted at 50 and 100μM concentrations while
there was little eﬀect on basolateral adherence. Overall membrane ca-
pacitance was most eﬀected at 100μM concentration, but also showed
some recovery in impedance at subtoxic (50 μM) and high concentra-
tion (100 μM) measurements (Fig. 3).
3.4. Expression of functional markers
Hepatocyte nuclear factor 4α (HNF4α) directly regulates expression
of CYP3 A4, a major metabolic enzyme within the liver [18]. While
HNF4α did not show a statistically signiﬁcant increase at either 25 or
50μM, its up regulation at 25μM and low expression at 50μM correlated
with the pattern seen in CYP3 A4 where expression was signiﬁcantly up
regulated at low concentration (25μM) CPZ (p < 0.05) when com-
pared with untreated control. However, at 50μM CPZ, CYP3 A4 ex-
pression was down regulated when compared with 25μM (p < 0.05)
(Fig. 4).
3.5. Anti-apoptotic pathway
Viability was unaﬀected with no initiation of apoptotic pathways as
can be seen by the ratio of apoptotic and anti-apoptotic markers BAX
and BCL-2 between 25 and 50 μM concentrations of CPZ (p < 0.0001).
This was further supported by a progressive and signiﬁcant induction of
Bcl-2, from control to 50 μM CPZ treated cells (Fig. 6).
3.6. Changes in expression of biliary transporters
Expression of eﬄux phospholipid transporter ABCB4 showed a
concentration dependant increase in response to CPZ, which was sig-
niﬁcantly diﬀerent from control at 50μM (p < 0.001). ABCB1 re-
sponsible for xenobiotic eﬄux, was non-signiﬁcantly down regulated at
25μM when compared to control. At 50μM ABCB1 was signiﬁcantly up
regulated as compared to 25μM CPZ, though not signiﬁcantly diﬀerent
from control. Whereas, bile acid export pump ABCB11 was not detected
at 25μM and was signiﬁcantly down regulated at 50μM compared to
control (p < 0.01) (Fig. 7).
When compared with untreated control, CPZ treated cells showed a
statistically signiﬁcant concentration dependant response in expression
of pro-inﬂammatory cytokines IL-6 and TNF-α. Up regulation of IL-6 at
50 μM was almost a 10 fold increase compared to untreated control
(p < 0.005) while TNFα showed a 2 fold increase at 25 μM
(p < 0.001) and a 9 fold increase at 50 μM (p < 0.005) when com-
pared to untreated control (Fig. 5).
The gradual increase in expression of anti-oxidant regulator NRF2,
with increasing concentrations of CPZ, though not statistically sig-
niﬁcant is suggestive of cellular activation of this defence pathway,
which is associated with CPZ induced cholestasis (Fig. 5).
4. Discussion
The HepaRG™ co-culture provides a unique opportunity to study the
interaction of hepatocytes and cholangiocytes when challenged with
CPZ.
Here we show, a novel approach to developing a mechanistic un-
derstanding of CPZ toxicity combining cell viability assays, impedance
based quantitative measurements of cell membrane changes and gene
expression data.
CPZ is a neuroleptic drug used in the treatment of schizophrenia
that has been known to cause acute IHC. Current models fail to fully-
explain the mechanism of CPZ toxicity, whether because of interspecies
variation using animal derived hepatocytes or poor in vitro metabolic
functionality found in human hepatic cell lines.
Tavoloni and Boyer describe the toxic eﬀects of speciﬁc CPZ me-
tabolites and how they aﬀect bile secretion in rats leading to IHC [19].
They propose that any induction of the pathways involved in the me-
tabolism of these toxic molecules could account for the idiosyncratic
presentation. While their study highlights the many and varied meta-
bolites of CPZ and how they interact with the cell membrane altering
bile acid secretion, there is still an issue of interspecies variation. For
example, bile acids vary in quality and quantity between animal and
human counterparts and therefore results cannot be directly correlated
[19]. Other studies using CPZ attribute incidence of IHC and cellular
damage to increased inﬂammatory response [20]. However, many of
these studies pre-treated cells to induce inﬂammation before use [21].
Fig. 2. Measurement of Cell Viability after 24 h
incubation with increasing concentrations of
CPZ: Cell viability of HepaRG cells were as-
sessed using A) Promega total ATP assay and B)
PrestoBlue resazurin based assay.
Quantiﬁcation of metabolic proﬁciency after
24 h exposure to various concentrations of CPZ
shows no signiﬁcant loss of viability at any
concentration (Data indicative of 3 in-
dependent experiments with 3 technical re-
plicates each experiment).
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A fully functional in vitro human model would address issues of
interspecies variation and would not need induction. Primary human
hepatocytes are diﬃcult to obtain and culture and can introduce
variability due to intra-species variation, and many immortalised cell
lines do not retain metabolic proﬁciency, which would preclude them
for needing pre-conditioning. Therefore, we use the human HepaRG cell
line which diﬀers from traditional hepatic in vitro models, as it is pro-
pagated from a bipotent hepatoblast-like cell and diﬀerentiated with
dimethylsulfoxide to a co culture of hepatocyte and cholangiocyte-like
cells. These maintain intrinsically high CYP activity, and functionality
Fig. 3. Real time impedance measurements using ECIS Zθ system A) Post-challenge impedance kinetics showing 24hours treatment with CPZ in conﬂuent HepaRG
cells: CPZ caused a dose-dependent decline in normalized resistance - a global indicator of cellular status. B) Rb (cell-cell tight junctions): CPZ disrupted tight
junctions in a concentration- and time- dependent manner; compared with control values. Subjecting HepaRG to 100μM CPZ caused Rb to decrease after 6 h with
marginal recovery around 15 h. C) α basolateral adhesion): Cell-substrate adhesion disruption was detected in a concentration dependent manner, suggesting some
loosening of cells from the electrode surface. At 100μM CPZ, cell adhesiveness decreased, but showed an increase around 10 h suggesting re-adherence of cells. D) Cm
(membrane capacitance): membrane capacitance, reﬂecting cell membrane integrity, was signiﬁcantly compromised at 100μM CPZ beginning at 2 h post treat-
ment. Some increase in Cm of 100μM CPZ was seen around 10 h which is consistent with the basolateral adhesion (α) and further indicating some cellular com-
pensatory eﬀect.
Fig. 4. Eﬀects of CPZ on mRNA expression of
HNF4α and CYP3A4: mRNA expression of (A
nuclear factor HNF4α and (B CYP3 A4 in the
HepaRG cells comparing untreated control,
25 μM and 50 μM CPZ. Fold change is relative
to untreated control. Results show concentra-
tion dependent downregulation of mRNA levels
of CYP3 A4 and HNF4α in 50μM CPZ treated
cells compared with untreated control.
Expression of CYP3 A4 was signiﬁcantly upre-
gulated at 25μM of CPZ (p < 0.05) when
compared with untreated control which may be
indicative of a compensatory response by the
cell before signiﬁcant downregulation at
50 μM. Fold change (± SD), data taken from
three independent experiments using three
technical replicates per experiment.
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akin to freshly isolated primary human hepatocytes. They also remain
stable for several weeks, oﬀering the opportunity to assess membrane
transport proteins in a diﬀerentiated co-culture model known to me-
tabolise both phase I and II enzymes [6]. Other studies of CPZ induced
toxicity which used the HepaRG cells have attributed incidence of IHC
to increased inﬂammatory response leading to oxidative stress and
mitochondrial toxicity, which damages tight junctions and contributes
to a more ﬂuid cellular membrane [1]. Within our model we also show
evidence of membrane changes via a concentration dependant in-
ﬂammatory response most likely due to oxidative stress. However, this
may represent an adaptive or compensatory response as suggested by
partial recovery of impedance-based parameters with regards to overall
cell membrane integrity.
There are many elements to the tight junction complex consisting of
adherens, claudin and occludin proteins. ZO1 is attached to both
claudin and occludin proteins and is anchored to the F-actin cytoske-
leton. For this reason, we performed parallel staining of the F-actin
cytoskeleton and membrane protein ZO1 which shows a loss of F-actin
and ZO1 in a concentration dependent response to CPZ (Fig. 1).
Viability assays (PrestoBlue and ATP) showed no diﬀerences in
viability between control and CPZ treated cells at the concentrations
tested (Fig. 2). This appeared to contradict immunocytochemistry
images where Hoechst staining for nuclei showed very few cells re-
mained attached at 100μM CPZ 24 h post-treatment. We speculate non,
or loosely, adherent cells which remained viable, would have been
washed away during processing for staining, as these wash steps tend to
be more aggressive than those between viability assays. [22] A measure
of cell viability can also be seen when considering the ECIS data. At
24 h post treatment there is evidence that cells are still covering elec-
trodes at the 50 and 100 μM concentrations. Although membrane in-
tegrity is compromised, it is possible that the cells which remain are still
metabolically active. As the PrestoBlue assay measures the cells meta-
bolic proﬁciency, it could be that at 100 μM, though there are fewer
cells, metabolic activity may still be present.
While it has been well documented that CPZ causes cholestasis
within a relatively short time frame [23] there are no in vitro studies to
conﬁrm or quantify how quickly the toxic eﬀects of CPZ take eﬀect. A
real-time, label free method showing immediate cause and eﬀect of
drug toxicity would give more insight into pathophysiology.
Deconvolving impedance data showed a concentration dependent
loss of tight junctions, and signiﬁcant loss of membrane integrity at
100μM concentration within 6 h of CPZ treatment.
Some recovery of membrane integrity was seen after 6 h at 50 and
100μM. (Fig. 3). This result diﬀers from our previously published ECIS
monitoring of APAP which was used as a model hepatotoxin and
showed concentration dependant damage to tight junctions with no
recovery8. Signatures of dose dependant toxicity have also been de-
monstrated using other cell lines and treatments for example skin and
retinal cells exposed to various wavelengths of light [24–26],. As ECIS is
a highly sensitive technology, it is possible that diﬀerent signatures
could be seen depending on the mechanism of toxicity and further work
with cholestatic compounds may establish an ECIS speciﬁc signature.
Metabolic activity and CYP functionality are important in detox-
iﬁcation of the cellular environment and support adaptive processes
within the cell. Here both CYP3A4 and its regulator HNF4α showed a
trend of up-regulation at the lower concentration indicating a possible
adaptive response to low levels of toxicity within the cellular environ-
ment. (Fig. 4) The inhibition of CYP3A4 and HNF4α at the higher
concentration of 50 μMmay correlate with the up-regulation seen in IL6
and TNFα (Fig. 5), inducers of oxidative stress, which are known to
cause down-regulation of these markers [20].
Expression of IL6 seen in instances of cellular stress and disease, is
also known to induce the anti-apoptotic BCL2 pathway, shown in Fig. 6
and may also be indicative of a compensatory response [27]. A con-
centration dependant non-signiﬁcant increase of NRF2, which regulates
expression of antioxidant proteins, was also seen in response to CPZ and
further suggests counteraction to toxicity.
In this study, we have not measured levels of TNFα and IL6 in
media, instead we have looked at mRNA expression for these cytokines.
We have shown that they are signiﬁcantly diﬀerent from control which
indicates that changes in mRNA expression are due to CPZ treatment.
Inhibition of the bile acid transporter ABCB11 in the HepaRG model
may point towards an additional mechanism of CPZ mediated choles-
tasis. Accumulation of bile acids has been shown to target the tight
junction complex and more speciﬁcally ZO1 protein [28]. This may be
the causative factor in the degradation of tight junctions and ﬂuctuation
of membrane integrity.
We also assessed xenobiotic and phospholipid transporters ABCB1
and ABCB4 and show a concentration dependant up-regulation of both
genes which was signiﬁcantly increased at 50 μM, indicative of an
adaptive response at the cellular level. (Fig. 7). Polymorphisms of
ABCB1 and ABCB4 have been associated with various forms of cho-
lestasis and may go some way to addressing the idiosyncratic pre-
sentation of cholestasis caused by CPZ within a given population
[29–32]. Within this model, these genes are up-regulated in response to
sub toxic CPZ concentrations. We speculate that the inability to
Fig. 5. Expression of cellular defence system and pro-inﬂammatory markers.
Expression of the oxidative defence and pro-inﬂammatory genes NRF2, TNFα and IL6 show a trend of upregulation at 25 and 50 μM treatment with CPZ compared to
control with signiﬁcant upregulation at 50 μM in both IL6 and TNFα
A) The mRNA expression of the oxidative defence gene NRF2 is increased in 50 μM treated cells when compared to untreated control. Though no signiﬁcant
diﬀerence is reported this trend is in line with both TNFα and IL6. Data taken from four independent experiments with three technical replicates per experiment B)
Results show signiﬁcant upregulation of mRNA expression of TNFα between 25 μM and 50 μM treated cells (p < 0.001) compared to untreated control. C)
Expression of IL6 shows concentration dependent increasing trend when compared with untreated control, showing signiﬁcance at 50μM (p < 0.005). Data taken
from three individual experiments with three technical replicates per experiment.
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upregulate these transporters due to polymorphism or mutation may
result in CPZ induced IHC and could explain why certain individuals are
more susceptible than others.
5. Conclusion
Here we present a novel approach to forming a mechanistic view of
CPZ toxicity
encompassing traditional cell viability assays, impedance based
quantitative measurements and molecular investigation. CPZ treated
HepaRG were viable and retained membrane integrity however, baso-
lateral adherence and tight junctions were reversibly compromised.
Gene expression analysis showed evidence of an adaptive response to
CPZ treatment. Oxidative stress caused by inﬂammatory cytokines
TNFα and IL6, known to down-regulate CYP3A4 activity, may have also
contributed to the trend for increased NRF2 expression. In this model
bile acid transporter ABCB11 was down regulated, this causes accu-
mulation of bile acids leading to loss of tight junctions. Further evi-
dence of an adaptive response lies in the up regulation of anti-apoptotic
gene BCL2, xenobiotic and phospholipid transporters ABCB1 and
ABCB4 also support an adaptive response to CPZ treatment. We spec-
ulate that the idiosyncratic presentation of CPZ induced IHC may be
due to polymorphisms in ABCB1 and ABCB4 transporters, as some in-
dividuals are therefore unable to up regulate membrane bound trans-
porters resulting in continued hepatic injury.
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